id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2023-D-5016-0002,FDA,FDA-2023-D-5016,"Protocol Deviations for Clinical Investigations of Drugs, Biological Products, and Devices; Guidance for Industry - Draft Guidance",Other,Guidance,2024-12-30T05:00:00Z,2024,12,2024-12-30T05:00:00Z,2025-03-01T04:59:59Z,2025-10-16T09:00:23Z,,1,0,0900006486894c0f
FDA-2023-D-5016-0001,FDA,FDA-2023-D-5016,"Protocol Deviations for Clinical Investigations of Drugs, Biological Products, and Devices; Draft Guidance
for Industry; Availability",Notice,Notice of Availability,2024-12-30T05:00:00Z,2024,12,2024-12-30T05:00:00Z,,2024-12-30T17:22:51Z,2024-31261,0,0,09000064868947c7